The biopharmaceutical industry stands at the threshold of a new therapeutic modality. Antibody-drug conjugates (ADCs) established the clinical and commercial viability of targeted delivery; now, antibody-oligonucleotide conjugates extend this paradigm into genetic medicine—replacing cytotoxic payloads with oligonucleotides capable of modulating gene expression, splicing, or transcript stability. Yet the manufacturing complexity of AOC CDMO services far exceeds conventional antibody outsourcing. Service providers must integrate three distinct technological disciplines—antibody engineering, oligonucleotide chemistry, and bioconjugation process science—into a single, quality-controlled development and manufacturing continuum. For drug developers, identifying a bioconjugation CDMO partner possessing this cross-functional integration represents a critical-path bottleneck: without it, programs stall at feasibility assessment. The global AOC CDMO market, valued at USD 418 million in 2025, is projected to reach USD 1,172 million by 2032 at a 15.8% CAGR, reflecting the expanding pipeline of conjugates entering clinical development.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Antibody-Oligonucleotide Conjugates (AOC) CDMO – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Antibody-Oligonucleotide Conjugates (AOC) CDMO market, including market size, share, demand, industry development status, and forecasts for the next few years.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6694409/antibody-oligonucleotide-conjugates–aoc—cdmo
The global market for Antibody-Oligonucleotide Conjugates (AOC) CDMO was estimated to be worth USD 418 million in 2025 and is projected to reach USD 1,172 million, growing at a CAGR of 15.8% from 2026 to 2032. The global gross margin of AOC CDMO services in 2025 is estimated at 30%-45%, reflecting the premium pricing commanded by integrated bioconjugation CDMO platforms capable of cross-technology development.
Defining AOC CDMO Services: Cross-Technology Integration Mandate
Antibody-Oligonucleotide Conjugates CDMO refers to contract development and manufacturing services for AOC molecules, typically covering antibody preparation, oligonucleotide synthesis and modification, linker and conjugation process development, analytical method development and characterization, quality studies, technology transfer, GMP manufacturing, and clinical-to-commercial supply. By combining the targeting capability of antibodies with the gene-modulating function of oligonucleotides, antibody-oligonucleotide conjugates are designed to enable more selective delivery and therapeutic intervention—addressing the long-standing challenge of achieving tissue-specific oligonucleotide delivery without reliance on local administration or lipid nanoparticle formulations. This therapeutic mechanism places uniquely high demands on antibody engineering, oligonucleotide chemistry, conjugation control, purification, structural characterization, and regulatory compliance. The upstream supply chain mainly includes antibody bulk substance, oligonucleotide raw materials and amidite building blocks, linkers, conjugation reagents, purification media and chromatography resins, analytical consumables, and GMP packaging materials. Downstream customers are primarily innovative pharmaceutical companies, biotechnology firms, and drug developers focused on oligonucleotide conjugates and next-generation bioconjugated therapeutics. Notably, Avidity Biosciences’ delpacibart etedesiran (AOC 1001), which achieved positive Phase 1/2 data in myotonic dystrophy type 1 in mid-2024 with sustained DMPK knockdown exceeding 50%, represents the most clinically advanced program validating the AOC modality—a catalyst directly stimulating CDMO service demand.
Market Maturity Assessment: Technology Exploration to Industrial Capability Building
The AOC CDMO market remains in a transition stage from technology exploration toward industrial capability building. Unlike traditional antibody outsourcing or stand-alone oligonucleotide outsourcing, this segment requires a significantly higher level of cross-technology integration. Service providers must support antibody development and manufacturing while simultaneously managing oligonucleotide synthesis, modification, conjugation process development, purification, analytical characterization, and quality control within a unified operational framework. As the concept of next-generation conjugated therapeutics continues to evolve—with companies exploring AOCs for oncology, neuromuscular disorders, cardiovascular disease, and metabolic indications—customer expectations are moving beyond single-module outsourcing toward integrated platform services capable of supporting early development, clinical supply, scale-up, and eventual commercial manufacturing. Competition in AOC CDMO services remains nascent; the number of companies with demonstrably established service capabilities is limited, and the sector continues to be strongly driven by technology depth and project-specific execution quality.
Technical Complexity and Demand Concentration
AOC drug development poses inherent complexity because it combines both antibody and oligonucleotide development logic, typically involving greater process complexity, deeper analytical work, and more demanding quality studies than conventional biologics or general conjugates. Key technical challenges include achieving site-specific conjugation with consistent drug-to-antibody ratio, managing oligonucleotide stability during conjugation and purification, characterizing conjugates with orthogonal analytical methods, and controlling aggregate formation. Consequently, market demand today concentrates around feasibility studies, conjugation optimization, analytical method establishment, sample preparation, and support from preclinical programs into early clinical stages. Service platforms demonstrating capability to extend into scale-up and reliable supply will more likely gain long-term customer confidence—a dynamic structurally similar to the ADC CDMO market circa 2015-2017, where early technical leaders captured disproportionate market share as the modality advanced toward commercialization.
Future Development Trajectories: Integration, End-to-End Expansion, and Technical Refinement
Future development is expected to move in three directions: platform integration, end-to-end service expansion, and greater technical refinement. Platform integration means service providers will continue strengthening coordination across antibody, oligonucleotide, and conjugation modules, with early leaders such as Lonza and WuXi XDC leveraging existing ADC infrastructure to accelerate AOC service capability deployment. Lonza’s expansion of its Visp, Switzerland bioconjugation facility in Q1 2025 specifically allocated capacity to oligonucleotide conjugate programs. End-to-end expansion reflects the growing preference among sponsors for partners capable of handling process development, quality studies, clinical supply, and commercial manufacturing within a unified workflow, thereby reducing technology transfer risks and operational gaps that historically plague multi-vendor outsourcing models. Greater technical refinement manifests in stronger demand for site-specific conjugation chemistries, structural consistency control via multi-attribute methods, complex impurity profiling for linker-oligonucleotide byproducts, delivery optimization through receptor-mediated uptake characterization, and comprehensive regulatory documentation support aligned with evolving ICH M14 and regional oligonucleotide guidance documents. As more delivery technologies and conjugation strategies mature—including ligand-mediated targeting beyond antibodies—AOC CDMO services will likely expand from early feasibility-driven demand toward broader late-stage and industrial manufacturing requirements.
Market Drivers and Structural Constraints
Key drivers of market growth include continued advances in oligonucleotide therapeutics and targeted delivery technologies, rising investment by innovative drug developers in new conjugated modalities beyond ADCs, and increasing reliance on outsourcing models in complex drug development where internal capability building requires prohibitive capital and timeline commitment. The clinical validation provided by Avidity’s AOC 1001 program and the growing pipeline of preclinical and Phase 1 AOC assets have materially de-risked investor perception of this modality, accelerating venture funding and partnership activity. Structural constraints include long technical chains spanning multiple scientific disciplines, difficult scale-up from milligram conjugation to multi-gram GMP batches, demanding analytical characterization requiring high-resolution mass spectrometry and multi-angle light scattering capabilities, lengthy quality standard establishment for products lacking pharmacopoeial monographs, and the need for close coordination between separate antibody and oligonucleotide supply systems typically managed by different vendors. For service providers, expertise in only one side of the value chain is becoming increasingly insufficient. Over time, market leadership will consolidate among companies combining technical integration, development efficiency, robust quality systems, sophisticated project management, and industrial execution within comprehensive service platforms—a competitive logic benefiting established antibody-oligonucleotide conjugates CDMO players with demonstrable cross-discipline delivery track records.
The Antibody-Oligonucleotide Conjugates (AOC) CDMO market is segmented as below:
By Company
Porton Pharma Solutions
Lonza
3PBIOVIAN
Abzena
GenScript
WuXi XDC
NJ Bio
Medicilon
Segment by Type
GMP Services
Non-GMP Services
Segment by Application
Pharmaceutical Companies
Biotechnology Companies
Academic and Research Institutions
Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
